Patents Assigned to Virttu Biologics Limited
-
Patent number: 11612626Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.Type: GrantFiled: February 13, 2020Date of Patent: March 28, 2023Assignees: Virttu Biologics Limited, The University of SheffieldInventors: Joe Conner, Munitta Muthana, Claire Elizabeth Lewis
-
Publication number: 20210169955Abstract: An oncolytic herpes simplex virus is disclosed for use in a method of treating cancer, the method comprising administering one or more doses of an oncolytic herpes simplex virus effective to induce a Th1 immune response in the subject, and optionally administering a therapeutically effective amount of an immune checkpoint inhibitor.Type: ApplicationFiled: September 3, 2020Publication date: June 10, 2021Applicant: VIRTTU BIOLOGICS LIMITEDInventor: Joe Conner
-
Patent number: 10813958Abstract: An oncolytic herpes simplex virus is disclosed for use in a method of treating cancer, the method comprising administering one or more doses of an oncolytic herpes simplex virus effective to induce a Th1 immune response in the subject, and optionally administering a therapeutically effective amount of an immune checkpoint inhibitor.Type: GrantFiled: January 19, 2018Date of Patent: October 27, 2020Assignee: Virttu Biologics LimitedInventor: Joe Conner
-
Publication number: 20200289590Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.Type: ApplicationFiled: February 13, 2020Publication date: September 17, 2020Applicants: Virttu Biologics Limited, The University of SheffieldInventors: Joe Conner, Munitta Muthana, Claire Elizabeth Lewis
-
Publication number: 20200078426Abstract: An oncolytic herpes simplex virus is disclosed for use in a method of treating cancer in a human subject, the method comprising administering to the human subject at least one dose of oncolytic herpes simplex virus by infusion to the blood, wherein the oncolytic herpes simplex virus reaches cells of the cancer in which it replicates.Type: ApplicationFiled: September 17, 2019Publication date: March 12, 2020Applicant: VIRTTU BIOLOGICS LIMITEDInventor: Joe Conner
-
Publication number: 20200000861Abstract: Oncolytic herpes simplex virus for use in a method of treating cancer in a pediatric subject having a tumor are described, wherein the oncolytic herpes simplex virus is administered intratumorally.Type: ApplicationFiled: June 20, 2019Publication date: January 2, 2020Applicant: Virttu Biologics LimitedInventors: Joe Conner, Timothy Cripe
-
Publication number: 20180071348Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.Type: ApplicationFiled: March 11, 2016Publication date: March 15, 2018Applicants: VIRTTU BIOLOGICS LIMITED, THE UNIVERSITY OF SHEFFIELDInventors: Joe CONNER, Munitta MUTHANA, Claire Elizabeth LEWIS
-
Patent number: 9085777Abstract: The present invention includes a method of generating a mutant Herpes Simplex Virus (HSV). In one embodiment, the generated HSV genome includes nucleic acid encoding a nucleic acid sequence of interest. In one step, a nucleic acid vector is provided which includes a nucleic acid encoding first and second site specific recombination sequences and a nucleic acid encoding a nucleic acid sequence of interest between said site specific recombination sequences an HSV is provided, the genome of which comprises third and fourth site specific recombination sequences In another step, the nucleic acid vector and HSV are contacted together with one or more recombinase enzymes capable of catalyzing site specific recombination between the site specific recombination sequences of said nucleic acid vector and said HSV. Another step includes identifying HSV containing the nucleic acid sequence of interest. In some embodiments, the methods are conducted in a cell-free system.Type: GrantFiled: May 4, 2007Date of Patent: July 21, 2015Assignee: Virttu Biologics LimitedInventor: Joe Conner
-
Patent number: 8980282Abstract: Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.Type: GrantFiled: April 2, 2008Date of Patent: March 17, 2015Assignee: Virttu Biologics LimitedInventor: Joe Conner
-
Patent number: 8969063Abstract: A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.Type: GrantFiled: March 12, 2012Date of Patent: March 3, 2015Assignee: Virttu Biologics LimitedInventors: Joe Conner, Susanne Moira Brown
-
Patent number: 8778684Abstract: There is provided an HSV complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cells, by incorporating an antibody binding domain into one or more viral glycoproteins.Type: GrantFiled: April 13, 2011Date of Patent: July 15, 2014Assignee: Virttu Biologics LimitedInventors: Susanne Moira Brown, Joe Conner
-
Patent number: 8530437Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.Type: GrantFiled: May 6, 2009Date of Patent: September 10, 2013Assignees: Sloan Kettering Institute for Cancer Research, Virttu Biologics LimitedInventors: Susanne Moira Brown, Paul Dunn, Bhuvanesh Singh, Ian Ganly
-
Publication number: 20120237999Abstract: A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.Type: ApplicationFiled: March 12, 2012Publication date: September 20, 2012Applicant: VIRTTU BIOLOGICS LIMITEDInventors: Joe Conner, Susanne Moira Brown
-
Publication number: 20120141418Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.Type: ApplicationFiled: November 28, 2011Publication date: June 7, 2012Applicants: THE WISTAR INSTITUTE, Virttu Biologics LimitedInventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
-
Patent number: 8163292Abstract: A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.Type: GrantFiled: February 15, 2008Date of Patent: April 24, 2012Assignee: Virttu Biologics LimitedInventors: Joe Conner, Susanne Moira Brown